Healthcare distributor Cencora (NYSE: COR) announced better-than-expected revenue in Q2 CY2025, with sales up 8.7% year on year to $80.66 billion. Its non-GAAP profit of $4 per share was 4.2% above analysts’ consensus estimates.

Is now the time to buy COR? Find out in our full research report (it’s free).

StockStory’s Take

Cencora’s third quarter results outperformed Wall Street’s expectations on both revenue and adjusted profit, but the market reacted negatively, reflecting investor concerns about slower growth in key areas. Management attributed the quarter’s outcomes to continued strength in U.S. Healthcare Solutions, particularly specialty distribution and higher utilization of pharmaceuticals, including GLP-1 products. However, CEO Robert Mauch and CFO James Cleary acknowledged moderating growth in GLP-1s and biosimilars, and highlighted the impact of losing a large, low-margin grocery customer. Cleary also flagged persistent weakness in the international segment, especially in global specialty logistics and consulting, where a sluggish biotech funding environment and subdued clinical trial activity weighed on results.

Looking forward, Cencora’s guidance is shaped by ongoing momentum in its core U.S. Healthcare Solutions segment and improving trends in specialty pharmaceuticals. Management expects continued gains from the RCA acquisition and investments in digital and physical infrastructure, but remains cautious regarding international recovery. Cleary emphasized that “we aren’t assuming the same level of outperformance that we’ve had in the recent past,” pointing to a slower rebound in the international business and a normalization of growth in GLP-1s. The company is also closely monitoring regulatory and policy changes, including tariffs and drug pricing reforms, which could influence both margins and supply chain stability.

Key Insights from Management’s Remarks

Management highlighted that robust specialty business, disciplined portfolio management, and digital transformation initiatives were pivotal in the quarter, while international challenges and sector-specific headwinds tempered overall optimism.

• Specialty distribution momentum: Cencora’s specialty business, especially in retina and oncology, drove strong operating income growth, supported by the recent RCA acquisition and robust demand from physician practices and health systems.
• GLP-1 and biosimilar trends: While GLP-1 pharmaceuticals continued to contribute to revenue growth, management noted a deceleration in volume expansion. Biosimilar drugs also played a dual role, supporting margins but moderating top-line growth as adoption increased in Medicare Part B and D.
• International segment pressures: Weakness persisted in international specialty logistics and consulting, reflecting a subdued environment for biotech funding and clinical trial starts. Management reported some sequential improvement but expects a gradual recovery, with growth returning as clinical trial activity picks up.
• Digital and operational investments: Ongoing investment in digital infrastructure and advanced analytics is a core part of Cencora’s strategy to improve efficiency and customer service, underpinning both current results and future competitiveness.
• Portfolio review and resource allocation: CEO Robert Mauch stressed the company’s focus on rigorous portfolio discipline, noting that Cencora is prioritizing growth-aligned areas and deprioritizing segments seen as less strategic, including elements of the international and animal health businesses.

Drivers of Future Performance

Cencora’s outlook is anchored in sustained U.S. specialty growth, selective investment, and cautious international recovery amid evolving regulatory and industry headwinds.

• U.S. specialty strength to continue: Management expects the U.S. Healthcare Solutions segment to remain the primary growth engine, driven by increased utilization of specialty drugs, stable demand from physician practices, and ongoing benefits from the RCA integration. However, executives cautioned that future growth rates are likely to normalize as recent outperformance is tempered by tougher comparisons and market maturation.
• International segment recovery uncertain: Despite some early signs of improvement, management remains cautious about the international segment’s rebound, attributing the slow recovery to persistent weakness in biotech and logistics. The company expects easier comparisons and potentially better demand as clinical trial activity stabilizes, but flagged timing as uncertain and dependent on external factors.
• Policy and industry risks: Cencora is closely watching policy shifts around tariffs and drug pricing reforms. CFO James Cleary stated that while current tariffs have not materially impacted results, evolving regulations and supply chain risks could introduce new headwinds, especially for branded and generic pharmaceuticals. The company is advocating for patient access and supply chain continuity while preparing for possible market disruptions.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will track (1) the pace of specialty growth within the U.S. Healthcare Solutions segment, particularly contributions from recently acquired RCA, (2) the trajectory of international segment recovery as biotech funding and clinical trial activity evolve, and (3) the impact of regulatory changes, including tariffs and drug pricing reforms, on both revenue and supply chain resilience. The effectiveness of Cencora’s digital transformation and portfolio review initiatives will also be important signposts for future performance.

Cencora currently trades at $289.99, in line with $292.32 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.